Immunomedics initiated at Morgan StanleyImmunomedics started with an Overweight rating, $38 target at Morgan Stanley. As previously reported, Morgan Stanley analyst Matthew Harrison initiated Immunomedics with an Overweight rating, stating that he expects IMMU-132 to be approved by its PDUFA date in January 2019 and expects rapid adoption of the drug after that. The drug is initially focused in late-line triple negative breast cancer, but he believes expansion to earlier lines of therapy can drive over $1B in peak sales, Harrison tells investors. He set a $38 price target on Immunomedics shares. Read more at: https://thefly.com/landingPage...Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. * $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.